Department of Infectious Disease, Institute of Infectious Disease and Epidemiology, Tan Tock Seng Hospital, Singapore, Singapore.
Curr Infect Dis Rep. 2015 Jan;17(1):456. doi: 10.1007/s11908-014-0456-3.
H5N1 influenza continues to smolder in Southeast Asia over the past 5 years, but the emergence of H7N9 in China in 2012 raised concerns for a new avian influenza threat. In contrast with H5N1 with over 650 confirmed cases over 11 years, H7N9 has infected over 450 persons within 2 years. The case fatality rate for H7N9 (35 %) is lower than for H5N1 (60 %) or H10N8 (67 %) but is comparable to that for the Middle East respiratory syndrome coronavirus (MERS CoV), another emerging zoonosis with travel-associated importations. Exposure to poultry and fomites are considered the likely sources of infection for H7N9, H5N1, and H10N8, with limited human-to-human transmission in close contacts. Most cases have occurred in local populations of affected countries, and travel-related risk can be mitigated by avoiding exposure. Vaccines, antivirals, and other therapeutics remain in development stage or of modest benefit for dangerous infections carrying high morbidity and mortality.
在过去的 5 年中,H5N1 流感继续在东南亚地区潜伏,但 2012 年中国 H7N9 的出现引起了人们对新的禽流感威胁的关注。与过去 11 年中已有超过 650 例确诊病例的 H5N1 不同,H7N9 在两年内已感染超过 450 人。H7N9 的病死率(35%)低于 H5N1(60%)或 H10N8(67%),但与另一种新兴人畜共患病中东呼吸综合征冠状病毒(MERS-CoV)相当,后者也与旅行相关的输入病例有关。接触禽类和污染物被认为是 H7N9、H5N1 和 H10N8 的可能感染源,在密切接触者中,人与人之间的传播有限。大多数病例发生在受影响国家的当地人群中,通过避免接触可以减轻与旅行相关的风险。疫苗、抗病毒药物和其他疗法仍处于开发阶段,对于携带高发病率和死亡率的危险感染,其益处有限。